| scholarly article | Q13442814 |
| P2093 | author name string | Dani Cohen | |
| Malabi M Venkatesan | |||
| Marcia K Wolf | |||
| Thomas L Hale | |||
| David E Katz | |||
| Jacob Atsmon | |||
| Miri Yavzori | |||
| Nadav Orr | |||
| Paull Radu | |||
| Raid Kayouf | |||
| Ruhama Ambar | |||
| Tamar Halperin | |||
| Tamar Sela | |||
| Zivit Klein | |||
| P2860 | cites work | Activation of the CDC42 effector N-WASP by the Shigella flexneri IcsA protein promotes actin nucleation by Arp2/3 complex and bacterial actin-based motility | Q24683572 |
| Nod1 detects a unique muropeptide from gram-negative bacterial peptidoglycan | Q29618544 | ||
| Global burden of Shigella infections: implications for vaccine development and implementation of control strategies | Q33749510 | ||
| Identification of icsA, a plasmid locus of Shigella flexneri that governs bacterial intra- and intercellular spread through interaction with F-actin | Q33859430 | ||
| Vaccination against shigellosis with attenuated Shigella flexneri 2a strain SC602 | Q33876803 | ||
| Phase I evaluation of delta virG Shigella sonnei live, attenuated, oral vaccine strain WRSS1 in healthy adults | Q34120926 | ||
| Identification and cloning of a novel plasmid-encoded enterotoxin of enteroinvasive Escherichia coli and Shigella strains | Q35455031 | ||
| Shigellosis: innate mechanisms of inflammatory destruction of the intestinal epithelium, adaptive immune response, and vaccine development | Q35696566 | ||
| Presence of specific immunoglobulin A-secreting cells in peripheral blood after natural infection with Shigella sonnei | Q37125747 | ||
| Immunoglobulin M, A, and G antibody response to lipopolysaccharide O antigen in symptomatic and asymptomatic Shigella infections | Q37167794 | ||
| Diarrheal disease during Operation Desert Shield | Q39090383 | ||
| Deletion in the Shigella enterotoxin genes further attenuates Shigella flexneri 2a bearing guanine auxotrophy in a phase 1 trial of CVD 1204 and CVD 1208. | Q39146446 | ||
| Construction of a stable attenuated Shigella sonnei DeltavirG vaccine strain, WRSS1, and protective efficacy and immunogenicity in the guinea pig keratoconjunctivitis model | Q39573053 | ||
| Two studies evaluating the safety and immunogenicity of a live, attenuated Shigella flexneri 2a vaccine (SC602) and excretion of vaccine organisms in North American volunteers. | Q40469794 | ||
| Interruption of shigellosis by hand washing | Q43324822 | ||
| Construction and evaluation of a double mutant of Shigella flexneri as a candidate for oral vaccination against shigellosis | Q44965347 | ||
| Epidemiology of Shigella infections in two ethnic groups in a geographic region in southern Israel | Q47231371 | ||
| A modified Shigella volunteer challenge model in which the inoculum is administered with bicarbonate buffer: clinical experience and implications for Shigella infectivity. | Q54158784 | ||
| Increase of trimethoprim resistance among Shigella species, 1975-1988: analysis of resistance mechanisms. | Q54323072 | ||
| Prevalence of Shigella Enterotoxin 1 among Shigella Clinical Isolates of Diverse Serotypes | Q54601009 | ||
| Shigella Infections in the United States, 1974-1980 | Q70251641 | ||
| Family illness associated with Shigella infection: the interrelationship of age of the index patient and the age of household members in acquisition of illness | Q70731769 | ||
| P433 | issue | 12 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | Israel | Q801 |
| Shigella sonnei | Q6382438 | ||
| P304 | page(s) | 8027-8032 | |
| P577 | publication date | 2005-12-01 | |
| P1433 | published in | Infection and Immunity | Q6029193 |
| P1476 | title | Community-based safety, immunogenicity, and transmissibility study of the Shigella sonnei WRSS1 vaccine in Israeli volunteers | |
| P478 | volume | 73 |
| Q57170680 | A Phase I trial to evaluate the safety and immunogenicity of WRSs2 and WRSs3; two live oral candidate vaccines against Shigella sonnei |
| Q91827516 | A phase I trial of WRSS1, a Shigella sonnei live oral vaccine in Bangladeshi adults and children |
| Q40970058 | A study of different buffers to maximize viability of an oral Shigella vaccine |
| Q37668395 | An update on vaccines against Shigella |
| Q34394744 | Characterization of WRSs2 and WRSs3, new second-generation virG(icsA)-based Shigella sonnei vaccine candidates with the potential for reduced reactogenicity |
| Q37067290 | Clinical Trial of an Oral Live Shigella sonnei Vaccine Candidate, WRSS1, in Thai Adults |
| Q36844719 | Clinical trials of Shigella vaccines: two steps forward and one step back on a long, hard road |
| Q30443288 | Enteric infections, diarrhea, and their impact on function and development |
| Q37066116 | Establishment of a Shigella sonnei human challenge model in Thailand |
| Q57068847 | Evaluation of a conjugate vaccine platform against enterotoxigenic Escherichia coli (ETEC), Campylobacter jejuni and Shigella |
| Q42262595 | Evaluation of virulent and live Shigella sonnei vaccine candidates in a gnotobiotic piglet model |
| Q40460000 | Immunogenicity and characterization of WRSF2G11: a second generation live attenuated Shigella flexneri 2a vaccine strain. |
| Q36689023 | Live-attenuated Shigella vaccines |
| Q100731064 | NAIP-NLRC4-deficient mice are susceptible to shigellosis |
| Q87281013 | Oral administration of live Shigella vaccine candidates in rhesus monkeys show no evidence of competition for colonization and immunogenicity between different serotypes |
| Q46799503 | Phase 1 clinical trial of live attenuated Shigella dysenteriae type-1 DeltaicsA Deltaent Deltafep DeltastxA:HgR oral vaccine SC599 in healthy human adult volunteers. |
| Q34974972 | Prevention and self-treatment of traveler's diarrhea |
| Q38068954 | Recent progress towards development of a Shigella vaccine |
| Q38294092 | Safety and colonization of two novel VirG(IcsA)-based live Shigella sonnei vaccine strains in rhesus macaques (Macaca mulatta) |
| Q30369367 | Safety and immunogenicity of WRSd1, a live attenuated Shigella dysenteriae type 1 vaccine candidate. |
| Q39056494 | Safety and immunogenicity of a candidate bioconjugate vaccine against Shigella dysenteriae type 1 administered to healthy adults: A single blind, partially randomized Phase I study |
| Q43432983 | Shigella sonnei vaccine candidates WRSs2 and WRSs3 are as immunogenic as WRSS1, a clinically tested vaccine candidate, in a primate model of infection. |
| Q56383780 | Shigellosis |
| Q34518265 | Status of vaccine research and development for Shigella |
| Q46354821 | Two live attenuated Shigella flexneri 2a strains WRSf2G12 and WRSf2G15: a new combination of gene deletions for 2nd generation live attenuated vaccine candidates |
| Q36969851 | Type III secretion systems and disease |
| Q28305456 | Type VI secretion is a major virulence determinant in Burkholderia mallei |
| Q36728805 | Use of attenuated bacteria as delivery vectors for DNA vaccines |
| Q33578045 | Vaccines against human diarrheal pathogens: current status and perspectives |
| Q35887055 | Vaccines for viral and bacterial pathogens causing acute gastroenteritis: Part II: Vaccines for Shigella, Salmonella, enterotoxigenic E. coli (ETEC) enterohemorragic E. coli (EHEC) and Campylobacter jejuni. |
Search more.